STAT+: Combination treatment reduces risk of tumor progression in aggressive form of breast cancer, study shows
The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study presented at an ASCO meeting.
CHICAGO — A treatment that combines two different types of cancer-fighting medicines — Gilead Sciences’ Trodelvy with Merck’s Keytruda — reduced the risk of tumor progression by more than one-third in women with an aggressive form of breast cancer.
The results reported Saturday from the randomized Phase 3 study called ASCENT-04 could lead to a new treatment option for patients with newly diagnosed, metastatic, triple-negative breast cancer, experts said.
Gilead, which conducted the study, could also benefit from a boost in Trodelvy sales at a time when it faces competition from a similar drug made by AstraZeneca and Daiichi Sankyo.
